Are you looking to invest in the upcoming Infinium Pharmachem IPO? This blog post is here to give you all the information you need to make an informed decision. We'll be looking at the review of the IPO, the GMP live rates day by day with Kotak rates, the date and price band details, the market lot, the dates, and the promoter holding. Read on to find out more about the Infinium Pharmachem IPO and get all the information you need to make a smart investment.
Infinium Pharmachem IPO Review
Infinium Pharmachem is set to make its debut in the Indian stock market with its IPO. The company is engaged in the manufacture and sale of pharmaceutical products and has been a leader in the Indian market for many years. This IPO will be a great opportunity for investors to get exposure to this fast-growing sector.
The Infinium Pharmachem IPO will open on March 31 and close on April 5, 2023, with an offer price band of ₹135 per share and a minimum lot size of 1000 shares. The total size of the issue is ₹25.31 crores. The issue will be managed by Edelweiss Financial Services Ltd, HDFC Bank Limited and ICICI Securities Ltd as the book running lead managers (BRLMs).
In terms of financials, Infinium Pharmachem has posted consistent growth over the last three financial years. For FY2021, it reported revenues of ₹19.66 crores with a net profit of ₹2.03 crores, representing an attractive return on equity (ROE) of 12%. It has also reported healthy operating profits during this period indicating efficient management practices which have enabled it to maximise returns from its operations.
Currently, Infinium Pharmachem operates three production units located in Daman & Diu and Dadra & Nagar Haveli that are compliant with cGMP standards as prescribed by World Health Organisation (WHO) guidelines, highlighting its commitment towards quality standards in manufacturing processes. This should give potential investors comfort when considering investing in this issue as they can be assured that all safety protocols are being adhered to strictly during production processes at these facilities.
Overall, we believe that Infinium Pharmachem's current financials combined with its commitment towards quality standards make it an attractive investment proposition for those looking to gain exposure to pharma sector through IPOs
Infinium Pharmachem IPO GMP Live Rates day by day with Kotak rates.
Infinium Pharmachem recently announced their Initial Public Offering (IPO) and it is set to open on March 31, 2023. The company has fixed the IPO price band at ₹135 with a market lot of 1000 shares and aims to raise ₹25.31 crores via this public offering.
For investors looking to invest in Infinium Pharmachem IPO, understanding the Grey Market Premium (GMP) rates is important as they reflect the demand for an issue and help investors decide whether or not to invest in an issue. GMP live rates are available day by day with Kotak Securities, one of India's leading brokers providing services such as equity trading, mutual funds investments, commodity trading and portfolio management services.
Kotak Securities provides up-to-date GMP live rate information for Infinium Pharmachem’s upcoming IPO through its website and mobile app so that investors can stay informed about the latest developments regarding the IPO. This helps investors make informed decisions about their investments.
The GMP live rates provided by Kotak Securities are based on real-time market data which is constantly monitored by experienced professionals who have a deep understanding of stock markets and financial instruments. This ensures that investors get accurate information which helps them make better decisions while investing in Infinium Pharmachem’s upcoming IPO.
In addition to providing real-time GMP live rate information, Kotak Securities also offers research reports, technical analysis tools and other resources to help investors understand the current market trends before investing in Infinium Pharmachem’s upcoming IPO. These resources provide valuable insights into current market conditions which can be used by investors to make more profitable investment decisions when investing in any kind of security including IPOs like Infinium Pharmachem's upcoming offering.
Infinium Pharmachem IPO Date & Price Band Details
Infinium Pharmachem’s IPO date is March 31, 2023, with the close date being April 5, 2023. The price band of the Infinium Pharmachem IPO has been set at ₹135 per share with a market lot of 1000 shares. This means that investors must purchase a minimum of 1000 shares in order to participate in this public offering.
The company aims to raise approximately ₹25.31 crores from this upcoming IPO, which will be used for working capital requirements and general corporate purposes. In addition to raising funds for business operations, Infinium Pharmachem will also use these funds to strengthen their position in the marketplace by investing in research and development activities as well as expanding their product portfolio and overall production capacity.
It is important for investors to consider not just the price band but also other factors such as market demand, company fundamentals and peer companies while deciding whether or not they should invest in Infinium Phamachem’s upcoming IPO. Investors should also evaluate the company’s underlying financial performance before making an investment decision. Additionally, it is recommended that investors consult a financial advisor or professional consultant before investing in any public offering.
In summary, Infinium Pharmachem’s upcoming Initial Public Offering (IPO) offers investors an opportunity to invest in one of India's leading pharmaceutical companies at a fixed price band of ₹135 per share with a market lot of 1000 shares from March 31 - April 5, 2023. It is highly recommended that investors conduct thorough research on both the company's fundamentals and current market conditions before investing in any public offering like Infinium Pharmachem's upcoming IPO.
Infinium Pharmachem IPO Market Lot
Infinium Pharmachem's upcoming Initial Public Offering (IPO) has a market lot of 1000 shares. A market lot is the smallest number of shares that can be bought or sold in a single transaction. This means investors are required to purchase at least 1000 shares in order to participate in this IPO. The minimum application amount is fixed at ₹1,35,000 (1000 shares x ₹135). Investors looking to invest higher amounts can apply for multiple lots, subject to availability. For example, an investor looking to purchase 10,000 shares will have to apply for 10 market lots of 1,000 shares each and the total investment amount will be ₹13,50,000 (10 lots x 1,000 shares x ₹135).
The Benefits of applying through Market Lot: One of the key benefits of applying through Market Lot is that it helps reduce transaction costs as investors are required to make only one payment for all the lots purchased. Additionally, since one lot contains a minimum number of shares specified by the company issuing the IPO, it reduces the chances of mispricing due to a small quantity being traded. Furthermore, investing through market lots also helps create uniformity among buyers and sellers who are trading in large quantities and allows them to benefit from economies of scale by buying or selling at lower prices.
It’s important that potential investors understand their options before they invest in Infinium Pharmachem’s upcoming IPO and decide on how many market lots they need based on their financial goals and risk tolerance levels. Investors should do their research thoroughly before investing and always consult with an experienced financial advisor if needed.
Infinium Pharmachem IPO Dates
Infinium Pharmachem's upcoming IPO will begin on March 31, 2023 and close on April 5, 2023. This period of time is known as the offer period and it is when investors can apply for shares in the company. Once the offer period is over, applications will be assessed and allotment of shares will take place shortly after.
The initial allotment of shares to investors is based on a number of factors, such as demand, past performance, market conditions and other relevant data. Investors should make sure they understand all the terms and conditions associated with an IPO before investing their money. Additionally, they should also keep a check on any changes in Infinium Pharmachem's new issues price range or any other related parameters that may affect the allotment of shares.
Investors should also note that there is no guarantee that their application would be accepted for an IPO issue by Infinium Pharmachem. Therefore, it is important to thoroughly research all aspects related to this IPO before applying for it so as to make an informed decision about whether or not investing in this company could be beneficial for them in the long run.
Finally, once all these processes are completed, Infinium Pharmachem's new stock will become available to trade on NSE SME Exchange from April 12th onwards at its respective listing price. This marks the end of the entire IPO process and investors can start trading their allotted stocks right away!
Infinium Pharmachem IPO Promoter Holding
Infinium Pharmachem is an NSE SME IPO which will be open for subscription on March 31st, 2023. The company is owned, managed and controlled by its promoters, who are the key stakeholders of the company. Before investing in Infinium Pharmachem's upcoming IPO, it is important to understand their promoter holding structure.
As per the draft red herring prospectus filed with SEBI, Infinium Pharmachem's promoters hold a total of 11,716,000 equity shares out of the total issued and paid-up capital of 15 million equity shares. This translates to a 78% stake in the company. Of these 11.7 million equity shares held by promoters, 8 million are held by Mr. Pravin Mehta (promoter group A) and 3.7 million are held by Ms. Pallavi Pravinbhai Mehta (promoter group B). This shows that both promoters have equal stakes in the company and have an equal say in decision making process related to Infinium Pharmachem's business operations and other related matters.
It is also important to note here that Infinium Pharmachem has no pledged equity shares as reported on September 30th 2020. This means that all 11.7 million equity shares held by promoters are unencumbered and freely transferable – something that potential investors should take into account when evaluating this IPO for investment purposes.
In conclusion, it is clear that Infinium Pharmachem’s promoter holding structure should be taken into consideration before investing in their upcoming IPO as it provides insight into how much control each of the promoters have over their business operations and decisions related to said operations going forward. In addition to this information, investors should also research other aspects such as past performance data, market conditions and other relevant factors before investing in this IPO to ensure they make an informed decision about their investments.
Infinium Pharmachem IPO Form
Infinium Pharmachem is set to launch its IPO on March 31, 2023. The Infinium Pharmachem IPO form is available for download from the company’s website. The Infinium Pharmachem IPO form contains all the details about the company and its offerings. It includes information on the company’s business model, financial performance, prospects and more. Investors can also get detailed information about the pricing of the shares and how the IPO will be structured.
The Infinium Pharmachem IPO form should be filled in with accurate information as it will help investors make an informed decision about investing in this company’s stock. The form requires investors to provide their personal details such as name, address, PAN number and other necessary documents that are required for KYC verification. Once completed, investors can submit their forms online or send them in by post to Infinium Pharmachem's designated registrar office.
The Infinium Pharmachem IPO form also contains details about the allotment process and instructions on how to apply for shares in the offering. All applicants must ensure that they complete all parts of the forms accurately before submitting it either online or offline. Applicants must attach copies of relevant documents such as ID proof, address proof and PAN card along with their application forms before submission.
The Infinium Pharmachem IPO form can also be found on leading stock exchange websites like NSE SME IPOs where interested individuals can access it easily. To receive updates regarding any changes related to this offering, investors should subscribe to email notifications from these websites or follow relevant social media accounts of both NSE SME IPOs and Infinium Pharmchem Ltd..
Once submitted, investors will receive a copy of their application forms along with an acknowledgement slip which should be kept safe until further notice from the exchange or registrar office regarding allotment status or refunds if applicable. Henceforth it is important for every investor to read all sections carefully before filling out his/her application forms correctly and completely in order to prevent any errors that could lead to delay or rejection of applications during processing stage at exchanges or registrars office
Infinium Pharmachem Company Financial Report
Infinium Pharmachem is a pharmaceutical company based in India, with a primary focus on manufacturing and marketing active pharmaceutical ingredients (APIs) and intermediates. The company has been operating for over three decades and has become one of the leading API manufacturers in the country. As per their latest financial report, Infinium Pharmachem reported a consolidated revenue of ₹2617.72 million for FY2020-21, which is an increase of 8.14% from FY2019-20. This growth was aided by a strong performance from their formulations division, which witnessed a growth rate of 28.6%.
The company’s profit before tax for FY2020-21 was ₹121 million, an improvement of 493% from the previous year. Besides this, their net worth has increased to ₹1225 million as compared to ₹860 million in FY2019-20. The networth includes total equity share capital of ₹531 million along with reserves & surplus of ₹694 million as at March 31st 2021.
In addition, Infinium Pharmachem had total cash and cash equivalents amounting to approximately ₹411 million as at March 31st 2021 while they also hold investments amounting to around ₹1190 million in various mutual funds and bonds. Furthermore, the company reported no debt or borrowings on its balance sheet as at March 31st 2021.
All this indicates that Infinium Pharmachem is well placed financially ahead of its proposed IPO offering in 2023 and should be able to meet all its commitments towards investors if it goes public through an Initial Public Offering (IPO).
Infinium Pharmachem IPO Valuation – FY2022
Infinium Pharmachem IPO Valuation – FY2022: Infinium Pharmachem has set their IPO price band of ₹135 per share in order to raise ₹25.31 crores with a market lot of 1000 shares. This gives the company a pre-IPO valuation of approximately ₹1450 crores. The company’s financial performance in the fiscal year 2022 will be an important factor that decides its post-IPO valuation.
Infinium Pharmachem has reported healthy growth in revenues and profits for FY2020-21, and is expected to continue this trend for the current fiscal year as well. This can be attributed to their ongoing efforts to expand their operations in India as well as overseas markets. In addition, they are also looking at new product launches and expanding their product portfolio, which should further add value to the company’s bottomline. As such, these factors combined could contribute to a higher post-IPO market capitalization for Infinium Pharmachem when compared to its pre-IPO valuation of ₹1450 crores.
Another important factor that will determine Infinium Pharmachem’s post-IPO valuation is investor appetite for pharma stocks in general. The performance of other similar companies listed on Indian stock exchanges like Divi's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., among others, will have an impact on the trading activity of Infinium Pharmachem after it goes public. If investors continue to show strong interest in pharmaceutical stocks then it may result in higher valuations for Infinium Pharmachem following its IPO launch date of March 31st 2023.
Therefore, it is evident that there are multiple factors that may affect Infinium Pharmachem's pre- and post-IPO valuations during FY2022 and beyond. Investors should keep an eye on these factors before investing their hard earned money into the company's upcoming public offering.
Company Promoters
The company promoters of Infinium Pharmachem are Mr. Anil Kumar Bisaria, Mrs. Rajni Bisharia, and their family members. They hold a majority stake in the company, with 61.54% of the total shareholding as of March 31st 2021. This suggests that they have a strong control over the business decisions and strategic directions taken by the company.
Mr. Anil Kumar Bisaria is the founder-director of Infinium Pharmachem and has been associated with it since its inception in 2009. He has an academic background in Chemical Engineering from Jodhpur University, India and holds several prestigious positions within the industry such as Member of Indian Drug Manufacturers Association (IDMA) Governing Council and Chairman – Regulatory Affairs Sub-Committee at IDMA Governing Council. His professional experience in the pharma industry spans over two decades and he holds expertise in formulating strategies to drive growth for pharmaceutical companies through innovative approaches for product development, manufacturing operations & cost optimization initiatives, and regulatory compliance management systems.
Mrs Rajni Bisharia is also a director on the board of Infinium Pharmachem since 2015 and is responsible for overseeing financial operations, legal & compliance issues related to running a pharmaceutical business in India & abroad, taxation matters & government liaison activities including obtaining various approvals from drug regulators for product registration & launch plans across different countries including USA, Europe & South East Asia markets etc.. She has worked with leading MNCs such as Pfizer Ltd., Sun Pharmaceuticals Ltd., Hoechst Marion Roussel Ltd., etc during her professional career spanning more than 20 years now. She holds a degree in Commerce from Delhi University along with an Executive MBA Degree from IIM Bangalore which provides her deep understanding of finance & accounts related matters apart from other topics like strategy formulation etc..
Infinium Pharmachem enjoys committed support from its promoters who have been involved with day-to-day management activities right since its inception which reflects their trustworthiness towards shareholders’ interests especially when it comes to protecting them during price fluctuations or any market volatility that may arise due to macroeconomic factors or unforeseen events affecting pharma sector stocks at large scale.
Infinium Pharmachem IPO Registrar
The Infinium Pharmachem IPO Registrar is Karvy Fintech Private Limited. Karvy Fintech Private Limited is a part of the larger Karvy Group, which is one of India’s largest and most respected financial service groups. The Karvy Group has over three decades of experience in the financial services industry, providing corporate and individual clients with a full range of services including investment banking, stock broking, mutual fund management, portfolio management services, loan syndication, debt syndication and much more.
Karvy Fintech Private Limited has been appointed as the registrar to the Infinium Pharmachem IPO. As such they are responsible for managing all aspects of the IPO process including investor registrations and allotment of shares. They will also handle all communications related to the IPO, such as sending out prospectus and other important documents to investors before the issue opening date. Investors who wish to apply for shares in Infinium Pharmachem can do so through any approved broker or directly from Karvy Fintech Private Limited online or via their offices located across India.
As an experienced registrar whose services have already been utilized by many well-known companies in India for their IPOs, Karvy Fintech Private Limited brings with them years of expertise in successfully handling several complicated processes related to public issues like that proposed by Infinium Pharmachem. Investors should feel confident that their investments are secure with a reliable partner such as Kavy Fintech Private Limited at hand throughout this process.
What is Infinium Pharmachem IPO?
Infinium Pharmachem IPO is an Initial Public Offering (IPO) by Infinium Pharmachem, a pharmaceutical company based in India. Through this IPO, the company seeks to raise ₹25.31 crores by offering its equity shares at a price band of ₹135 per share, with a market lot of 1000 shares. This offering will provide investors an opportunity to invest in one of India’s leading pharmaceutical companies and benefit from the growth potential that this sector offers.
The company's promoters are Mr. Anil Kumar Bisaria and Mrs. Rajni Bisharia, who have been involved with the company since its inception and have committed support for shareholders' interests. Karvy Fintech Private Limited has been appointed as the registrar to the Infinium Pharmachem IPO and will handle all aspects of the IPO process including investor registration and allotment of shares.
Infinium Pharmachem has offered a wide range of products such as APIs, intermediates, custom synthesis services etc., which are used for various therapeutic applications across different stages of drug discovery & development process. The company has built a strong customer base in both domestic & international markets and is currently expanding its manufacturing capabilities through strategic collaborations with partners in order to further enhance their presence in these markets.
Infinium Pharmachem also benefits from GMP certification which ensures that they meet international standards for quality control & safety across their operations within Indian markets as well as around the world. The success of any public issue depends largely on investor appetite and Infinium Pharmachem expects strong demand from institutional investors looking for exposure to pharma stocks due to their long-term growth potential in India & abroad alike. Investors should take into account all factors before investing in this IPO offering by Infinium Pharmachem.
0 Comments